Glofinn America, LLC - GLO PRP

09/01/2021

https://medicalxpress.com/news/2021-08-platelet-rich-plasma-treatment-efficacy-osteoarthritis.html

A pilot study conducted by researchers at Baylor College of Medicine combined wearable technology and patient-reported outcomes to assess the efficacy of platelet-rich plasma (PRP) treatment in osteoarthritis (OA).

07/20/2021

https://www.yahoo.com/lifestyle/kate-beckinsale-47-gets-prp-therapy-for-aging-dermatologists-call-the-blood-facial-a-magical-rejuvenating-serum-220343674.html?soc_src=social-sh&soc_trk=fb&tsrc=fb

Kate Beckinsale revealed her skin-care secret, and it is one dermatologists endorse. Here's what you need to know about platelet-rich plasma (PRP) therapy.

05/01/2021

[PRP Spine Trials]

Effect of Platelet-Rich Plasma on Intervertebral Disc Degeneration In Vivo and In Vitro: A Critical Review ´

Yvang Chang , 1,2 Ming Yang , 1,2 Song Ke , 1,2 Yu Zhang , 1,2 Gang Xu , 1,2 and Zhonghai Li 1,2 1 Department of Orthopaedics, First Affiliated Hospital of Dalian Medical University, Dalian, China 2 Key Laboratory of Molecular Mechanism for Repair and Remodeling of Orthopaedic Diseases, Liaoning Province, China Correspondence should be addressed to Gang Xu; 526423695@163.com and Zhonghai Li; lizhonghaispine@126.com Received 6 September 2020; Revised 2 November 2020; Accepted 4 November 2020; Published 23 November 2020 Academic Editor: Sidong Yang Copyright © 2020 Yvang Chang et al.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Intervertebral disc degeneration (IDD) is a globally occurring disease that represents a significant cause of socioeconomic problems. Currently, the main method for treating IDD is surgery, including discectomy and vertebral fusion. Several in vitro experiments demonstrated that platelet-rich plasma (PRP) could stimulate cell proliferation and extracellular matrix regeneration. Additionally, in vivo experiments have proven that PRP injection could restore intervertebral disc height. Clinical studies demonstrated that PRP injection could significantly relieve patient pain. However, further studies are still required to clarify the roles of PRP in IDD prevention and treatment. This review is aimed at summarizing and critically analyzing the current evidence regarding IDD treatment with PRP.

05/01/2021

before & after - male with thinning hair and pattern baldness. excellent result after several weeks.

05/01/2021

mid 60s male - prp treatment before and 3mo after. crown is most difficult to revive due to lack of active cells once baldness starts. good example of 1 session - sent in by a clinic in NYC

05/01/2021

prp hair growth
[before & after] - sent in by Canadian clinic

05/01/2021

facial - wrinkle treatment under eye

05/01/2021

[PRP Publication - joints]

Osteoarthritis of the shoulder in under-50 year-olds: A multicenter retrospective study of 273 shoulders by the French Society for Shoulder and Elbow (SOFEC)

Author links open overlay panelJeanKany1TewfikBenkalfate2LucFavard3PhilippeTeissier4ChristopheCharousset5Pierre HenriFlurin6BertrandCoulet7LaurentHubert8JérômeGarret9PhilippeValenti10Jean DavidWerthel11NicolasBonnevialle12French Society for Shoulder and Elbow (SOFEC)13

https://doi.org/10.1016/j.otsr.2020.102756Get rights and content


INTRODUCTION: Osteoarthritis (OA) of the shoulder in under-50 year-olds is rare, and treatment is delicate. Shoulder replacement incurs frequent long-term risk of progression and a high revision rate, making it unsuited to young active patients. The aim of the present study was to determine the epidemiology of shoulder OA in under-50 year-olds and to assess the clinical results of the various treatment options.

HYPOTHESIS: The main study hypothesis was that well-conducted non-operative treatment can allow shoulder replacement to be postponed. The secondary hypothesis was that anatomic total shoulder arthroplasty (TSA) is the treatment of choice when other options fail.

MATERIALS AND METHODS: A multicenter retrospective study included primary (POA) and post-instability osteoarthritis (PIOA) in patients aged ≤50 years at symptom onset. Exclusion criteria comprised post-traumatic OA, rheumatoid arthritis and necrosis. 266 patients for 273 shoulders were included from 13 shoulder surgery centers: 2 types of non-operative treatment (28 by platelet-rich plasma (PRP) and 88 by viscosupplementation), 73 arthroscopies, and 150 implantations (62 humeral hemiarthroplasties (HA), comprising 10 hemi-metal, 24 hemi-pyrocarbon and 28 hemi-resurfacing; 77 anatomic total prostheses, and 11 reverse prostheses). Minimum follow-up was 12 months for non-operative treatment and 24 months for arthroplasty (some patients having both). Endpoints comprised Constant score, Subjective Shoulder Value (SSV) and number of complications/revision procedures.

RESULTS: Mean age at treatment was 43 years (range, 23-65 years), with 75% male predominance. Symptom onset was earlier in PIOA than in POA: 36 vs. 39 years (range, 20-50 years). PRP and viscosupplementation postponed implantation by a mean 3.5 years in 86% of cases, as did arthroscopy in 56%. ER1 restriction was the most negative factor. At 74 months’ follow-up for HA and 95 months for TSA, mean Constant score was significantly lower for HA (56 vs. 67; p=0.004), with higher rates of complications (31% vs. 11%) and implant exchange (13% vs. 9%).

DISCUSSION/CONCLUSION: PRP, viscosupplementation and arthroscopy allow implantation to be postponed until the shoulder becomes stiff and painful. In case of failure, TSA is the most effective solution in the medium term.

LEVEL OF EVIDENCE: IV a; Therapeutic Study - Investigating the Results of Treatment

Read at: https://www.sciencedirect.com/science/article/abs/pii/S1877056820303479

Osteoarthritis (OA) of the shoulder in under-50 year-olds is rare, and treatment is delicate. Shoulder replacement incurs frequent long-term risk of p…

05/01/2021

[PRP Publication]

Does Intra-Articular Injection of Platelet-Rich Plasma Have an Effect on Cartilage Thickness in Patients with Primary Knee Osteoarthritis?

Noha M Abdel Baki 1, Zeinab O Nawito 1, Nehal M S Abdelsalam 2, Dina Sabry 3, Hossam Elashmawy 4, Nagy A Seleem 5, Azza Ali Abdel-Azeem Taha 6, Mohamed El Ghobashy 7

Affiliations expand

• PMID: 33459238

• DOI: 10.2174/1573397117666210114151701

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

OBJECTIVES: To determine the effect of intra-articular injection of platelet-rich plasma (PRP) in patients with primary knee osteoarthritis (OA) by clinical evaluation and ultrasonographic (US) assessment of cartilage thickness.

PATIENTS AND METHODS: A total of 100 patients with mild to severe primary knee OA using the Kellgren-Lawrence (K-L) grading scale were included and divided into two groups. Group I included 50 patients who were given two intra-articular knee injections of PRP, 1 week apart; Group II included 50 patients who received non-steroidal anti-inflammatory drugs (NSAIDs) and chondroprotective drugs. Functional assessment of all OA patients done using the basal WOMAC score, at 2 and 6 months.US assessment of femoral condylar cartilage thickness was conducted basally and at 6 months.

RESULTS: Improvement of WOMAC score was observed at 2 and 6 months in Group I following PRP injection compared to Group II (p values < 0.001), The improvement of WOMAC in Group I occurred in all severity degrees of OA (p < 0.001). Moreover, a significant increase in cartilage thickness at the intercondylar area (ICA) at 6 months relative to baseline assessment by US in Group I (p = 0.041) was found.

CONCLUSION: Treatment with PRP injections can reduce pain and improve knee function in patients with various degrees of articular degeneration. Further studies are needed to clarify the anabolic effect of PRP on the articular cartilage.

KEYWORDS: Osteoarthritis; WOMAC; cartilage thickness.; chondroprotective drugs; platelet-rich plasma; ultrasonography.